Zevra Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
Zevra Therapeutics, Inc. (ZVRA) reported Gain (Loss) on Extinguishment of Debt of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-05
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was -$2.76M.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was -$16.10M.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
- Zevra Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2018 was $2.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | -$2.76M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$2.76M 10-Q · filed 2026-05-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 derived: sum of 3 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-03-07 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $0.00 derived: sum of 3 quarters · filed 2023-03-07 | $0.00 derived: sum of 4 quarters · filed 2023-03-07 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 derived: sum of 3 quarters · filed 2023-03-07 | $789.00K derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $789.00K derived: sum of 3 quarters · filed 2023-03-07 | -$16.10M 10-K · filed 2023-03-07 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $789.00K derived: sum of 2 quarters · filed 2022-11-10 | -$16.10M 10-Q · filed 2022-11-10 | -$16.10M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $789.00K 10-Q · filed 2022-08-12 | -$16.10M 10-Q · filed 2022-08-12 | -$16.10M derived: sum of 3 quarters · filed 2022-08-12 | -$16.10M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$16.89M 10-Q · filed 2022-05-12 | -$16.89M derived: sum of 2 quarters · filed 2022-05-12 | -$16.89M derived: sum of 3 quarters · filed 2022-05-12 | -$16.89M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 derived: sum of 3 quarters · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | ||
| 2018-12-31 | $2.00K 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $0.00 derived: sum of 2 quarters · filed 2018-03-30 | $0.00 derived: sum of 3 quarters · filed 2018-03-30 | -$4.74M 10-K · filed 2018-03-30 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | -$4.74M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-K 3 month · filed 2017-08-10 | -$4.74M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$4.74M 10-K · filed 2018-03-30 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $0.00 derived: sum of 2 quarters · filed 2017-03-10 | $1.90M derived: sum of 3 quarters · filed 2017-03-10 | $1.90M 10-K · filed 2017-03-10 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $1.90M derived: sum of 2 quarters · filed 2016-03-16 | $1.90M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $1.90M 10-K · filed 2016-03-16 | $1.90M 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |